BioSpace News Archive

When moving to a new role at the same company, it’s important to create a transition plan, understand your responsibilities and expectations and get to know your new team.

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, welcomed investors, analysts and media to its well-attended investor day in New York City.

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology and immunology, today announced completion of enrollment for two clinical trials evaluating its ropeginterferon alfa-2b-njft (BESREMi®).

Tristan Jervis, Founder and Managing Director of Impact Shine Communications (www.impactshinecommunications.com), who has an established record of promoting the progression of CGT, is honoured to join the Advisory Committee of the Gene Forum, which provides a platform for further advancing the field of gene therapy.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN.

The Association for Diagnostics & Laboratory Medicine released the results of a survey that ADLM conducted to determine how the Food and Drug Administration’s final laboratory developed tests rule will impact patient access to essential tests.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented new data demonstrating for the first time the potential for redosing with an investigational, in vivo CRISPR/Cas9 genome editing therapy.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 national conference in Albuquerque, New Mexico from June 28-30, 2024.

VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, announced the voting results from its annual general meeting of shareholders held on June 25, 2024.